BioSpecifics Technologies Corp
BioSpecifics Technologies — Investor Presentation (March 2015)
24 slides from BioSpecifics Technologies's investor presentation, Mar 19, 2015
Slide 1: Innovators in the development & commercialization of injectable collagenase
Innovators in the development & commercialization of INJECTABLE COLLAGENASE a . BioSpecifics March 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. all statements other than statements of historical fact are “forward-looking statements”
Slide 3: BioSpecifics is a profitable, commercial-stage biopharma company
BioSpecifics is a profitable, commercial-stage biopharma company receiving increasing revenues for sales of collagenase clostridium histolyticum or CCH (XIAFLEX®) by partner Endo. Future revenue growth opportunities emerging from commitment to clinical development of new indications for CCH. CHNOLOG
Slide 4: Vast Potential of CCH
Vast Potential of CCH First-in-class, minimally invasive nonsurgical treatment for conditions caused by collagen accumulation with limited current treatment options BioSpecifics has positive clinical results in 12 indications: Dupuytren’s contracture? Frozen shoulder Scarred tendons — Peyronie’s dis
Slide 5: Auxilium Acquired by Endo International
Auxilium Acquired by Endo International As of January 29, 2015, Auxilium Pharmaceuticals, Inc. (Auxilium) is now a wholly-owned subsidiary of Endo International plc (Endo). = Cash and stock transaction for approximately $2.6B* Endo stock value appreciated ~20% from date of transaction announcement t
Slide 6: Marketed Indications for XIAFLEX
Marketed Indications for XIAFLEX Impressive Revenue Growth Revenue-Generating Products Dupuytren’s Approved in the U.S., EU, Canada & Australia; under Contracture review in Japan Peyronie’s Disease Approved in the U.S. and EU (as of January 2015)
Slide 7: XIAFLEX for Dupuytren's Contracture
XIAFLEX for Dupuytren’s Contracture First and Only FDA- and EMA-Approved Nonsurgical Treatment Collagen cord in hand causing one or more fingers to contract toward the palm; limits range of motion and Definition impairs quality of life 300K patients diagnosed annually in the U.S. Treatment of up to
Slide 8: XIAFLEX for Peyronie's Disease
XIAFLEX for Peyronie’s Disease Sobi Received Approval for XIAPEX in EU First and Only FDA- and EMA-Approved Nonsurgical Treatment Definition & Key Complications Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with pain with erection
Slide 9: Peyronie's Disease Market in the U.S.
Peyronie’s Disease Market in the U. Commercial success of XIAFLEX for Peyronie’s disease in 2014 exceeded expectations but still room for further market penetration given total number of patients and surgeries performed 95K patients diagnosed with 2013; likely underdiagnosed Approximately 400 urolog
Slide 10: XIAFLEX Pipeline Programs
XIAFLEX Pipeline Programs Future Revenue-Generating Opportunities se: Cellulite Phase 2b to initiate by year-end 2015 *Human Lipoma Complete enrollment in Phase 2 in 1H15 canine: Endo has license for further development Lipoma *Uterine Positive a Fibroids ae Capsular Contracture Pe eer of Breast *Bi
Slide 11: CCH for Frozen Shoulder Syndrome
CCH for Frozen Shoulder Syndrome Potential to be Only FDA Approved Nonsurgical Therapy Definition & Complications Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Common available treatment options are often painful and can Potential to be require an
Slide 12: Phase 2b Study of CCH in Frozen Shoulder
Phase 2b Study of CCH in Frozen Shoulder Study Design Objective & Rationale 321 Patients Enrolled at 35 Sites in the U.S. and Australia Outcome Measures “Source: Ausum Pharmaceutical Ine Double-blind, placebo-controlled study evaluating safety and efficacy in Stage 2 (frozen stage) unilateral idiopa
Slide 13: Phase 2b Study Results of CCH in FSS
Phase 2b Study Results of CCH in FSS Next Trial Expected to Start by Year-End 2015 _ Phase 2a Results Strong, similar drug effect for key measures including forward flexion, shoulder abduction, external and internal rotation across both Phase 2a ye and Phase 2b trials p40 Similar CCH patient improve
Slide 14: CCH for Cellulite
CCH for Cellulite Phase 2b Trial to Initiate by Year-End 2015 Skin dimpling as a result of collagen fibrous septae, occurring mainly Definition on the buttocks, lower limbs, and abdomen aoe Market Affects 85-98% of women (est.) and rarely in men peerny | et Potential to be first and only FDA-approve
Slide 15: CCH for Cellulite: Top-line Data from Phase 2a Study
CCH for Cellulite Top-line Data from Phase 2a Study Top-line Data from Phase 2a Study Mid and high level CCH doses demonstrated statistically significant improvement in cellulite across all endpoints 68% of mid and high dose groups reported being “Satisfied” or “Very Satisfied” with treatment. Well-
Slide 16: CCH for Human Lipomas
CCH for Human Lipomas Phase 2 Opt-In Study Managed by BioSpecifics Definition Encapsulated deposits of benign fatty tumors; detected as bulges under the skin Potential to be No FDA-approved pharmaceutical therapies available Only Approved Nopoaeical i eroey Surgery not practical for patients with mu
Slide 17: Positive Phase Clinical Trial Results
Positive Phase 2 Clinical Trial Results Reported in January 2014 Open label, dose escalation Phase 2 trial: Statistically significant (p<0.0001) reduction in primary endpoint of visible surface area of lipoma as measured by caliper, combining all patients Patients in highest dose group (75% of comme
Slide 18: CCH for Lipomas in Canines
CCH for Lipomas in Canines Endo Announced Interest in Further Development Key Complications Potential to be Only Approved Nonsurgical Therapy $500K Opt-In Payment to BioSpecifics Opt-In Based on Chien-804 Results Lipomas can cause seriously restrict motion in older dogs Surgery can be risky due to t
Slide 19: CCH for Uterine Fibroids
CCH for Uterine Fibroids Endo Announced Interest in Further Development Definition & Key Complications Potential to be Nonsurgical Therapy Option U.S. Market Opportunity Encouraging Preclinical Data Pain, decreased fertility, miscarriage, heavy menstrual bleeding and frequent urination ones Sten ase
Slide 20: Endo Partnership for Development and Commercialization of CCH
Endo Partnership for Development and Commercialization of CCH >$52.7M Received $52.7M received in licensing, sublicensing, milestone, COGS, and from Auxiliumto Date _—_"valty payments as of December 31, 2014 5 ais Low double digit royalties as % of net sales aren ac Additional mark-up on COGS onpiti
Slide 21: Corporate Highlights
Corporate Highlights Projected Revenue Growth from Higher Ro - Vast opportunity for growth in revenues from XIAFLEX sales and approval of CCH in new indications Strong IP portfolio Long-term patent protection for injectable collagenase: Dupuytren’s Contracture: XIAFLEX has Orphan Drug protection in
Slide 22: Consistently Profitable Annually
Consistently Profitable Annually Full Year 2014 Financial Highlights (unaudited) For the quarter ended For the year ended 12/31/14 12/31/13 12/31/14 12/31/13 Cash and equivalents, and investments $21,961,252 $12,591,825 Income Statement Revenues $4,650,485 $4,072,110 $14,077,056 $14,467,240 Other in
Slide 23: Anticipated Upcoming Milestones
Anticipated Upcoming Milestones Upcoming Milestones Hum: : ann O Complete enrollment in Phase 2 placebo-controlled opt-in trial in 1H15 pomas * ‘Uterine “ar a O Refining development plan Peyronie’s Dacae O Anticipated launch and building of sales momentum in the EU Dupuytren’s T " Contracture © Deci
Slide 24: Innovators in the development & commercialization of injectable collagenase
Innovators in the development & commercialization of INJECTABLE COLLAGENASE —_— “ BioSpecifics March 2015
Biospecifics Technologies — Investor Presentation (March 2015) on 6ix